Investigation of a tumour enzyme as a predictor of patient response to an Australian anti-cancer drug

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/630584

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

GSAO is a new cancer drug we have developed that is currently being trialed in cancer patients. Our investigation of how GSAO works has revealed that it needs to be activated by an enzyme expressed by certain types of cancers. This finding implies that GSAO should be more effective against cancers that make this enzyme. Our aim is to establish this concept in laboratory based experiments as a basis for selection of patients who are more likely to benefit from GSAO treatment.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $362,082.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Angiogenesis | Anti-cancer drugs | Drug development | Drug resistance | Gamma-glutamyl transferase | colorectal cancer | drug efficacy | drug-resistant tumours | ovarian cancer | pancreatic cancer

Related Links